Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 20/100

Failure Rate

11.7%

7 terminated/withdrawn out of 60 trials

Success Rate

63.2%

-23.3% vs industry average

Late-Stage Pipeline

58%

35 trials in Phase 3/4

Results Transparency

133%

16 of 12 completed trials have results

Key Signals

17 recruiting16 with results

Enrollment Performance

Analytics

Phase 3

35(58.3%)

Phase 2

21(35.0%)

N/A

3(5.0%)

Phase 1

1(1.7%)

60Total

Phase 3(35)

Phase 2(21)

N/A(3)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (60)

Showing 20 of 60 trials

NCT07578649Phase 3Not Yet Recruiting

Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer

Role: collaborator

NCT06824467Phase 3Recruiting

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Role: collaborator

NCT07216703Phase 3Recruiting

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Role: collaborator

NCT05548296Phase 2Recruiting

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

Role: collaborator

NCT04463771Phase 2Completed

Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

Role: collaborator

NCT03737643Phase 3Active Not Recruiting

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

Role: collaborator

NCT04931342Phase 2Active Not Recruiting

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

Role: collaborator

NCT05445778Phase 3Active Not Recruiting

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Role: collaborator

NCT07024784Phase 2Recruiting

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

Role: collaborator

NCT07214779Phase 3Recruiting

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Role: collaborator

NCT04269200Phase 3Active Not Recruiting

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

Role: collaborator

NCT07023627Phase 2Recruiting

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Role: collaborator

NCT06890338Phase 2Recruiting

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Role: collaborator

NCT05611931Phase 3Active Not Recruiting

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Role: collaborator

NCT07286266Phase 3Not Yet Recruiting

A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

Role: collaborator

NCT07286331Phase 3Not Yet Recruiting

A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)

Role: collaborator

NCT06459180Phase 3Active Not Recruiting

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Role: collaborator

NCT07213804Phase 3Recruiting

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

Role: collaborator

NCT07546500Phase 3Recruiting

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

Role: collaborator

NCT06989112Phase 3Recruiting

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Role: collaborator